Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission

BACKGROUND: Allogeneic hematopoietic stem cell transplantation with HLA-identical donors has been established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of 50% to 60%. OBJECTIVES: To analyze the overall survival of patients and identify factors that influence the outcomes of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan combination as conditioning regimen. METHODS: Twenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003 and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host disease and one extensive chronic graft-versus-host disease. RESULTS: The overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value = 0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graftversus-host disease and three relapses followed by renal failure (one) and infection (two). The cause of death could not be determined for two patients. CONCLUSION: The busulfan and melphalan conditioning regimen is as good as other conditioning regimens providing an excellent survival rate.

Saved in:
Bibliographic Details
Main Authors: Bueno,Nadjanara Dorna, Dulley,Frederico Luiz, Saboya,Rosaura, Amigo Filho,José Ulysses, Coracin,Fabio Luiz, Chamone,Dalton de Alencar Fischer
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300008
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842011000300008
record_format ojs
spelling oai:scielo:S1516-848420110003000082011-07-27Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remissionBueno,Nadjanara DornaDulley,Frederico LuizSaboya,RosauraAmigo Filho,José UlyssesCoracin,Fabio LuizChamone,Dalton de Alencar Fischer Stem cell transplantation Leukemia, myeloid, acute Drug toxicity Bone marrow transplantation Busulfan/administration &amp; dosage Combined modality therapy Cyclophosphamide/administration &amp; dosage Graft vs. Host disease Survival analysis Prognosis BACKGROUND: Allogeneic hematopoietic stem cell transplantation with HLA-identical donors has been established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of 50% to 60%. OBJECTIVES: To analyze the overall survival of patients and identify factors that influence the outcomes of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan combination as conditioning regimen. METHODS: Twenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003 and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host disease and one extensive chronic graft-versus-host disease. RESULTS: The overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value = 0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graftversus-host disease and three relapses followed by renal failure (one) and infection (two). The cause of death could not be determined for two patients. CONCLUSION: The busulfan and melphalan conditioning regimen is as good as other conditioning regimens providing an excellent survival rate.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.33 n.3 20112011-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300008en10.5581/1516-8484.20110050
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Bueno,Nadjanara Dorna
Dulley,Frederico Luiz
Saboya,Rosaura
Amigo Filho,José Ulysses
Coracin,Fabio Luiz
Chamone,Dalton de Alencar Fischer
spellingShingle Bueno,Nadjanara Dorna
Dulley,Frederico Luiz
Saboya,Rosaura
Amigo Filho,José Ulysses
Coracin,Fabio Luiz
Chamone,Dalton de Alencar Fischer
Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
author_facet Bueno,Nadjanara Dorna
Dulley,Frederico Luiz
Saboya,Rosaura
Amigo Filho,José Ulysses
Coracin,Fabio Luiz
Chamone,Dalton de Alencar Fischer
author_sort Bueno,Nadjanara Dorna
title Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
title_short Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
title_full Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
title_fullStr Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
title_full_unstemmed Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
title_sort busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
description BACKGROUND: Allogeneic hematopoietic stem cell transplantation with HLA-identical donors has been established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of 50% to 60%. OBJECTIVES: To analyze the overall survival of patients and identify factors that influence the outcomes of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan combination as conditioning regimen. METHODS: Twenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003 and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host disease and one extensive chronic graft-versus-host disease. RESULTS: The overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value = 0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graftversus-host disease and three relapses followed by renal failure (one) and infection (two). The cause of death could not be determined for two patients. CONCLUSION: The busulfan and melphalan conditioning regimen is as good as other conditioning regimens providing an excellent survival rate.
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300008
work_keys_str_mv AT buenonadjanaradorna busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
AT dulleyfredericoluiz busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
AT saboyarosaura busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
AT amigofilhojoseulysses busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
AT coracinfabioluiz busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
AT chamonedaltondealencarfischer busulfanandmelphalanasconditioningregimenforallogeneichematopoieticstemcelltransplantationinacutemyeloidleukemiainfirstcompleteremission
_version_ 1756423530193354752